Chemogenetics for cell-type-specific modulation of signalling and neuronal activity

被引：0
作者：
Hye Jin Kang
Takafumi Minamimoto
Jürgen Wess
Bryan L. Roth
机构：
[1] Yonsei University,Department of Biotechnology, College of Life Science and Biotechnology
[2] Sungkyunkwan University,Department of Biological Science
[3] National Institutes for Quantum Science and Technology,Department of Functional Brain Imaging
[4] Molecular Signaling Section,Department of Pharmacology
[5] NIDDK,undefined
[6] NIH,undefined
[7] University of North Carolina Chapel Hill School of Medicine,undefined
来源：
Nature Reviews Methods Primers | / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chemogenetics is an approach for engineering proteins to enable their modulation by otherwise inert small molecules. Although kinases, enzymes and ion channels have been used for chemogenetics, the most widely used platform is based on G protein-coupled receptors (GPCRs), using designer receptors exclusively activated by designer drugs (DREADDs). DREADDs have been used ubiquitously to modulate cellular signalling and neuronal activity and are a key technology for modern causal neuroscience. Here we provide a Primer on key aspects of DREADD technology, emphasizing how to reliably design and validate chemogenetic transducers and actuators. We also provide recommendations for the use of DREADDs for specialized applications including modulating metabolically essential peripheral tissues and distinct neuronal populations in non-human primates.
引用
收藏
相关论文
共 233 条
  • [1] Hopkins AL(2002)The druggable genome Nat. Rev. Drug Discov. 1 727-730
  • [2] Groom CR(2017)How ligands illuminate GPCR molecular pharmacology Cell 170 414-427
  • [3] Wacker D(2019)Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs Nat. Struct. Mol. Biol. 26 535-544
  • [4] Stevens RC(2008)Anatomical profiling of G protein-coupled receptor expression Cell 135 561-571
  • [5] Roth BL(2000)Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 351-354
  • [6] Roth BL(2003)Memantine in moderate-to-severe Alzheimer’s disease N. Engl. J. Med. 348 1333-1341
  • [7] Regard JB(2005)Voltage gated ion channels: targets for anticonvulsant drugs Curr. Top. Med. Chem. 5 15-30
  • [8] Sato IT(2016)Comprehensive characterization of the Published Kinase Inhibitor Set Nat. Biotechnol. 34 95-103
  • [9] Coughlin SR(2016)Allosteric modulation as a unifying mechanism for receptor function and regulation Cell 166 1084-1102
  • [10] Berman RM(2009)Predicting new molecular targets for known drugs Nature 462 175-181
12345678910